varicella-zoster%20virus%20infection%20(pediatric)
VARICELLA-ZOSTER VIRUS INFECTION (PEDIATRIC)
Varicella, also known as chickenpox, is a self-limited, benign disease caused by primary varicella-zoster virus (VZV) infection characterized by fever, malaise, and generalized pruritic vesicular rash.
The average incubation period is 14-16 days. It is transmitted via direct contact with vesicular fluid or inhalation of aerosolized respiratory secretions or via droplet route during face to face contact.
Hallmark sign is pruritic rash that begins in the scalp and face which eventually spreads to the trunks and extremities.

Varicella-zoster%20virus%20infection%20(pediatric) Treatment

Pharmacotherapy

Symptomatic Therapy

Antipruritics

  • Calamine lotion, tepid baths, cool compresses

Antipyretics

  • Eg Paracetamol
    • Aspirin should not be used in children because of its association with Reye’s syndrome
  • Provide symptomatic relief of fever

Analgesics

  • Eg Paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs); opioids may be considered in severe pain
  • May be used for relief of pain in herpes zoster infections

Local Therapy for Herpes zoster Lesions

  • Eg saline solution, mild antiseptics (Polyhexanide solution, Zinc oxide lotion)
  • May be used for acute vesicular or necrotizing herpes zoster lesions

Antivirals for Varicella

  • In otherwise healthy children, varicella is often benign and requires symptomatic care only
  • Varicella in otherwise healthy adolescents and in immunocompromised patients tends to be more severe and they may be treated with antivirals preferably within 24 hours
  • Considering that varicella is a self-limited disease, antivirals are not recommended for immunocompetent children ≤12 years of age; benefits should be weighed against adverse events and treatment cost

Aciclovir (PO/IV)

  • Aciclovir is recommended in VZV infections in immunocompromised patients
    • May be considered in patients with chronic cutaneous disorders, in patients with diseases that can be exacerbated by VZV infection (eg cystic fibrosis), otherwise healthy patients >12 years old or secondary household contacts, adolescents and adults
  • IV therapy should be used in severely immunocompromised patients and in severe infections
    • High-dose oral Aciclovir may be sufficient for mildly immunocompromised patients
  • Aciclovir is a guanosine analogue that is a competitive inhibitor of viral DNA polymerase
    • Limits viral replication and stops further spread of the virus to other cells
  • Shortens the duration of viral shedding, halts the formation of new lesions more quickly, accelerates the rate of healing in both immunocompetent and immunocompromised patients
    • This improvement is modest in the healthy individual but can reduce life-threatening complications in high-risk individuals

Famciclovir/Valaciclovir

  • Have been used in place of Aciclovir in otherwise healthy adolescents

Antivirals for Herpes zoster

  • Antiviral therapy is recommended in immunocompetent pediatric patients that are on chronic salicylic acid or glucocorticoid therapy
  • Also recommended for patients <50 years old at low risk or without complications but with trunk or extremities involvement
  • Intravenous (IV) Aciclovir is typically recommended in those with or at risk for complicated herpes zoster:
    • Head and/or neck involvement
    • Hemorrhagic/necrotizing lesions, involvement of >1 segment, aberrant vesicles/satellite lesions, or mucous membrane involvement
    • Immunocompromised patients
    • Visceral or CNS involvement
  • Primary goal of treatment in herpes zoster is to reduce acute pain and PHN
  • Therapy for herpes zoster should accelerate healing; limit the severity and duration of acute and chronic pain; reduce complications
  • When taken within 72 hours of symptom onset, oral antivirals have been shown to reduce severity and duration of symptoms
    • Most virus replication has ceased by 72 hours after the onset of rash but this may be substantially extended in immunocompromised patients
    • After 72 hours, antivirals should be considered if new vesicular lesions are continuing to appear 
  • Choice of agent depends on availability, cost, dosing schedule and patient preference
  • Options for patients with uncomplicated herpes zoster and at low risk for visceral dissemination are oral Aciclovir, Famciclovir and Valacyclovir

Aciclovir

  • Guanosine analogue that is a competitive inhibitor of viral DNA polymerase
    • Limits viral replication and stops further spread of the virus to other cells
  • May shorten the duration of illness
  • Several studies have shown that high-dose oral Aciclovir accelerates resolution of acute lesions and may reduce the risk for prolonged pain
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.